Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials

Ying Qiang Xiang, Wei Zheng, Shi Bin Wang, Xin Hu Yang, Dong Bin Cai, Chee H. Ng, Gabor S. Ungvari, Deanna L. Kelly, Wei Ying Xu, Yu-Tao Xiang

    Research output: Contribution to journalArticlepeer-review

    53 Citations (Scopus)


    This study aimed to conduct a meta-analysis of the efficacy and safety of adjunctive minocycline for schizophrenia. Randomized controlled trials (RCTs) comparing adjunctive minocycline with placebo in patients with schizophrenia were included in the meta-analysis. Two independent investigators extracted and synthesized data. Standard mean differences (SMDs), risk ratio (RR) ±95% confidence intervals (CIs) and the number-needed-to-harm (NNH) were calculated. Eight RCTs with 548 schizophrenia patient including 286 (52.2%) patients on minocycline (171.9±31.2 mg/day) and 262 (47.8%) on placebo completed 18.5±13.4 weeks of treatment. Meta-analyses of Positive and Negative Syndrome Scale (PANSS) (7 RCTs with 8 treatment arms)/Brief Psychiatric Rating Scale (BPRS) (1 RCT) total score [SMD: −0.64, (95%CI: −1.02, −0.27), P=0.0008; I2=74%], positive, negative and general symptom scores [SMD: −0.69 to −0.22 (95%CI: −0.98, −0.03), P=0.02–0.00001; I2=7–63%] revealed a significant superiority of adjunctive minocycline treatment over the placebo. There was no significant difference regarding neurocognitive function, discontinuation rate and adverse drug reactions between the two groups. This meta-analysis showed that adjunctive minocycline appears to be efficacious and safe for schizophrenia. Due to significant heterogeneity, future studies with a large sample size are needed to confirm these findings.

    Original languageEnglish
    Pages (from-to)8-18
    Number of pages11
    JournalEuropean Neuropsychopharmacology
    Issue number1
    Publication statusPublished - 1 Jan 2017


    Dive into the research topics of 'Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

    Cite this